Welcome to our dedicated page for Onconetix SEC filings (Ticker: ONCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Onconetix, Inc. (Nasdaq: ONCO) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures, offering a structured view of how this commercial-stage biotechnology company reports on its men’s health and oncology business. Onconetix’s filings span registration statements, current reports, and proxy materials, each providing different angles on its operations, capital structure, and governance.
Through registration statements on Form S‑1 and S‑1/A, Onconetix details equity financing arrangements such as PIPE transactions involving Series D and Series E convertible preferred stock and associated warrants, as well as an equity line of credit with Keystone Capital Partners. These documents describe the number of shares registered for resale, conversion and exercise prices, and the company’s status as a smaller reporting company and emerging growth company. They also explain the impact of the company’s 1‑for‑85 reverse stock split on share counts and per‑share data.
Current reports on Form 8‑K provide timely disclosure of material events, including PIPE financing closings, licensing agreements, promissory notes, Nasdaq listing notices, and strategic transactions. For example, 8‑K filings describe the terms of the Series D and Series E preferred stock and warrants, the licensing agreement between Proteomedix and Immunovia related to the PancreaSure pancreatic cancer test, and amendments and waivers associated with promissory notes tied to the ENTADFI asset acquisition.
The company’s definitive proxy statement on Schedule 14A outlines proposals for stockholder approval, such as director elections, ratification of the independent registered public accounting firm, and approvals required under Nasdaq rules for issuing common stock upon conversion of preferred stock and exercise of warrants. These materials also confirm the date and location of the annual meeting and summarize the board’s recommendations.
On Stock Titan, each new 10‑K, 10‑Q, 8‑K, S‑1, DEF 14A, or other filing is captured as it becomes available from EDGAR. AI-powered tools can be used to highlight key sections, such as risk factors, descriptions of Proclarix and ENTADFI, financing terms, and Nasdaq compliance disclosures. Users interested in insider activity can also review Form 4 filings, when available, to see reported transactions by directors and officers.
By using this page, investors and researchers can quickly locate Onconetix’s quarterly and annual reports, capital raising disclosures, and governance documents, and rely on AI summaries to interpret complex sections without reading every page of the underlying filings.
Thomas Meier, a director of Onconetix, Inc. (ticker: ONCO), reported changes to his restricted stock holdings on Form 4 dated 08/15/2025. The filing shows a modification of a previously granted restricted stock award (originally granted 09/26/2024) that changes the vesting date from August 31, 2025 to August 31, 2026, conditioned on continued service as a non-employee director through that date. The filing also reports a restricted stock award of 618 shares that will vest in full on August 31, 2026, and a reported amount of 39 shares related to the modified award, with 657 shares shown as beneficially owned following the transactions (amounts presented on a post 1-for-85 reverse split basis).
The filing discloses the issuer effected a 1-for-85 reverse split on June 13, 2025 and states all share amounts are post-split. No cash consideration is reported for the awards.
Onconetix, Inc. (ONCO) Form 4 filing reports changes to director Timothy Ramdeen's restricted stock awards. The filing shows the Original Award granted 9/26/2024 had its vesting date changed on 08/15/2025 from vesting in full on 08/31/2025 to vesting in full on 08/31/2026, contingent on continued service as a non-employee director. The issuer effected a 1-for-85 reverse stock split on 06/13/2025 and all amounts are shown post-split. The filing also reports a separate restricted stock award of 618 shares that will vest in full on 08/31/2026, subject to continued service. Reported transactions on 08/15/2025 include acquisitions and a disposition, with 658 shares shown as beneficially owned following the transactions.
Onconetix, a commercial-stage biotech that acquired Proteomedix and ENTADFI, reported sharply lower revenue and continuing losses for the quarter ended June 30, 2025. Revenue was $106,494 in the quarter (down from $704,848 a year earlier) and $208,124 for the six months (versus $1,405,281). The company recorded a quarterly net loss of $(2,372,442) and a six-month net loss of $(10,918,327), which included significant goodwill impairment charges (approximately $594,000 for the quarter and $11,512,000 for six months).
Balance-sheet and liquidity pressures are prominent: total assets fell to $19.12 million, goodwill to $18.12 million, cash was $283,515 at June 30, 2025 (approximately $0.2 million as of August 13, 2025), and the company used ~$3.41 million of operating cash in the first half of 2025. Management discloses a working capital deficit of ~$11.8 million and substantial doubt about the company’s ability to continue as a going concern without additional financing or use of the ELOC (approximately $17.0 million available as of August 13, 2025). Near-term debt obligations include Veru notes with principal payments due in August 2025.
Onconetix issued a promissory note to Keystone Capital Partners in the aggregate principal amount of $117,647.06 with an original issue discount of $17,647.06. The Keystone note is subordinate to existing obligations to Veru, does not initially bear interest, is payable upon receipt of sufficient proceeds from the Company’s equity line of credit with Keystone or on March 6, 2026, and unpaid amounts incur a 15% per annum late charge.
The Company also amended and restated the September Veru Note, increasing the principal by $100,000 to $5.1 million and amending the maturity to August 14, 2025. The filing documents multiple prior forbearance and waiver agreements with Veru that extended payment dates and increased the Company’s share of proceeds payable to Veru from 20% to 25% through June 30, 2025. Director Ajit Singh resigned effective August 10, 2025.